# Semaglutide FAQ: Direct Answers from the Trial Record

> Semaglutide questions answered plainly and cited from the trials: how it works, how much weight people lose, side effects, half-life, oral versus injection, and semaglutide versus tirzepatide.

Direct, plain answers — cited where they make a quantitative claim.

## What is semaglutide?

Semaglutide is a GLP-1 receptor agonist — an engineered copy of the gut hormone GLP-1 — that is FDA-approved for type 2 diabetes and chronic weight management. It lowers blood sugar, slows stomach emptying and quiets appetite. In the STEP 1 trial, once-weekly 2.4 mg produced a mean -14.9% body-weight change at 68 weeks versus -2.4% with placebo [1].

## How does semaglutide work for weight loss?

It reduces food intake by acting on appetite centers in the brain rather than by burning more energy. In rodent studies it reached the brainstem and hypothalamic arcuate nucleus, cutting intake and shifting food preference with no fall in energy expenditure [4]. The clinical result was a mean -14.9% body-weight change at 68 weeks in STEP 1 [1].

## How long does it take for semaglutide to work?

Appetite effects are often noticeable early, but the trial endpoints are measured over many months. STEP 1 measured its -14.9% mean weight change at week 68 — about 16 months — with the dose escalated gradually over the first weeks [1]. Two-year durability was shown in STEP 5 [8]. The headline figures describe sustained use, not a quick result.

## Why am I not losing weight on semaglutide?

This site reports trial averages, not individual guidance, so it cannot diagnose a personal result. STEP 1 reported a mean -14.9% change, but a mean is a group average — individual responses varied above and below it [1]. The dose was also escalated gradually in the trials, with the 2.4 mg maintenance dose reached only after several weeks [1]. Questions about your own response belong with a prescriber.

## How fast does semaglutide work?

The trials escalate the dose slowly and measure weight over many months rather than days. In STEP 1 the maintenance 2.4 mg dose was reached after a multi-week titration, and the -14.9% mean change was assessed at week 68 [1]. Some appetite effect is often reported early, but the established efficacy figures describe sustained treatment, not rapid loss.

## How long do you stay on semaglutide for weight loss?

The evidence frames it as long-term treatment. STEP 5 showed sustained weight loss over two years of continued use [8], and STEP 4 showed that stopping leads to regain — people who switched to placebo regained 6.9% from week 20 to 68 while those who continued lost a further 7.9% [9]. Duration for any individual is a clinical decision, not something this digest prescribes.

## How much weight can you lose on semaglutide in a month?

The trials report total change over many months, not per-month figures, and the dose is escalated gradually at the start, so early loss is typically modest. STEP 1 measured a mean -14.9% body-weight change over the full 68 weeks versus -2.4% with placebo [1]. This site does not provide monthly targets; per-month expectations for an individual are a matter for a prescriber.

## Do you regain weight after stopping semaglutide?

Yes, substantially. In the STEP 1 trial extension, participants regained a mean of roughly 11.6 percentage points of body weight within a year of stopping, and cardiometabolic improvements reverted toward baseline [17]. The STEP 4 withdrawal trial showed the same pattern after switching to placebo [9]. The weight loss is treatment-dependent, which is why the medicine is framed as chronic rather than curative.

## What is semaglutide used for?

Semaglutide is FDA-approved for type 2 diabetes, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and (2025) MASH, a fatty-liver disease [21]. Its weight indication rests on STEP 1 [1], its cardiovascular indication on SELECT [3], and its kidney evidence on FLOW [6].

## How does semaglutide work?

It activates the GLP-1 receptor, mimicking a gut hormone: it increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain appetite centers to reduce intake. In rodents it reached the brainstem, area postrema and hypothalamic arcuate nucleus, reducing food intake without lowering energy expenditure [4]. Engineering changes give it a roughly one-week half-life [11].

## What is the semaglutide dosage for weight loss?

In the weight-management trials, the subcutaneous schedule escalated from 0.25 mg once weekly to a 2.4 mg once-weekly maintenance dose, stepping up over several weeks [1]. That 2.4 mg dose produced the mean -14.9% body-weight change in STEP 1 [1]. These are the doses as documented in the trials and label, reported third person — not a recommendation for any individual.

## How many mg is 40 units of semaglutide?

This site reports doses only as they appear in the published trials and approved labeling, which express semaglutide in milligrams (for example, the 2.4 mg once-weekly maintenance dose in STEP 1) [1]. "Units" refers to volume markings on a syringe, which depend on the specific concentration of a given product, so this digest cannot convert units to milligrams. A pharmacist or prescriber can answer that for a specific product.

## What is compounded semaglutide?

Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than supplied as the approved manufactured product. It was permitted during a federally declared shortage (roughly 2022 to early 2025), during which regulators documented dosing errors, hospitalizations and products with unverified ingredients; the pathway was curtailed once the shortage resolved. The trial evidence summarized here — such as SUSTAIN-6 [2] — was generated with the approved product, not compounded versions.

## What are the side effects of semaglutide?

The dominant side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly mild-to-moderate and concentrated during dose escalation [13]. A dedicated safety review placed nausea at roughly one-third of patients and noted increased gallstone risk, with pancreatic and thyroid-cancer signals unconfirmed given low incidence [5]. SUSTAIN-6 also found more diabetic-retinopathy complications with rapid glucose correction (HR 1.76) [2].

## How long does semaglutide stay in your system?

Semaglutide has an elimination half-life of about one week (commonly cited as ~165-168 hours), so it is effectively cleared roughly five weeks after the last dose [11]. That long persistence is the basis for once-weekly dosing and is why labeling advises stopping well before a planned pregnancy [21].

## What is the half-life of semaglutide?

Approximately one week — commonly cited as about 165-168 hours — for both the subcutaneous and oral forms [11]. It results from strong, reversible binding to albumin via the fatty-acid side chain plus resistance to the DPP-4 enzyme, and it means steady drug levels persist for roughly five weeks after the final dose [11].

## Is oral semaglutide as effective as the injection?

This digest does not have a direct head-to-head efficacy figure to make that claim. Oral semaglutide is co-formulated with the absorption enhancer SNAC and has very low oral bioavailability (~0.4-1%), so it must be taken fasted with little water [22]. The weight-management efficacy figures on this site, such as the -14.9% STEP 1 result, come from the subcutaneous form [1]. Higher oral doses were studied for obesity separately.

## How long does it take for semaglutide to suppress appetite?

The mechanism that suppresses appetite is the central action on brain hunger circuits — in rodents, the brainstem and hypothalamic arcuate nucleus, reducing intake without lowering energy expenditure [4]. People often report a quieter appetite early, but this site reports that as anecdotal experience on the effects page; the controlled trials measured weight change over months, not appetite onset in days [1].

## Does semaglutide make you tired?

Tiredness is not a primary efficacy endpoint, but a real-world pharmacovigilance analysis of post-marketing reports characterized semaglutide's adverse-event profile, which is dominated by gastrointestinal events with additional signals under surveillance [14]. Fatigue is frequently described in patient communities, especially early and around injection day; this site presents that as anecdotal report on the [Semaglutide effects](/effects) page rather than as a trial finding.

## Is semaglutide a GLP-1?

Yes — semaglutide is a GLP-1 receptor agonist, an engineered analogue of the gut hormone glucagon-like peptide-1 that shares about 94% of its sequence [11]. It activates the same GLP-1 receptor the natural hormone uses, which is the basis for its insulin, appetite and gastric-emptying effects. Its cardiovascular benefit in type 2 diabetes was shown in SUSTAIN-6 (HR 0.74) [2].

## Does semaglutide cause hair loss?

A pharmacovigilance analysis found a reporting signal for alopecia with semaglutide [19], and a dermatology study tied telogen effluvium — reversible diffuse shedding — to the magnitude and rate of weight loss [20]. The signal is most consistent with rapid-weight-loss-associated shedding rather than a direct drug effect, and is generally reversible. SUSTAIN-6, by contrast, was a cardiovascular trial reporting reduced MACE (HR 0.74) [2].

## What is the difference between semaglutide and tirzepatide?

Semaglutide activates one gut-hormone receptor (GLP-1); tirzepatide is a dual agonist that activates two (GIP and GLP-1). In the SURMOUNT-5 head-to-head trial (n=751) in adults with obesity, tirzepatide produced greater mean weight loss at 72 weeks (-20.2% vs -13.7%; P<0.001) [7]. Semaglutide carries the larger dedicated cardiovascular and kidney outcome record (SELECT, FLOW) [3][6].

---

A measured, fully cited reading of the semaglutide trial record, with the weight-management evidence read first and the open questions kept in plain sight — an editorial digest, not a clinic, a prescriber, or a vendor.